Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host pharmacist Eric Christensen,

and I thank you for listening today. As always, go check out real life pharmacology.com.

Go snag your 31 page PDF on the top 200 drugs.

Fantastic study guide, refresher, whether you're in school or practicing out in the real

world. Definitely a great resource to have where I poured a little time into it and tried to

highlight some of the most highly testable things as far as board exams go, as well as some of the most

relevant things that actually occur in clinical practice. So go snag that for free,

simply for subscribing at real-life pharmacology.com. All right, so let's get into the drug of the

day today, and that is gliburide.

Brand name is diabetic, and this is an anti-diabetic agent, more specifically, a sulfonyria.

So if you remember back to the glypazide episode, this drug is in the same class.

Glybureate is in the same class, which can be a potential error, which I have seen glibyride

and glyphoside get mixed up because they do sound alike, they look alike.

Their dosing is in the range of each

other as well and the herbal sophoniger is, which stimulate that release of insulin. Dosing, you know,

I've seen 1.25 milligrams, you know, up to in the neighborhood of 15 to 20 milligrams a day.

It is a drug that I don't see very often anymore.

And there's a few reasons for that, and we'll kind of get into it.

But anyways, a class as a whole, sulfonyrias have, um, definitely gotten less and less popular, um,

due to their facts of hypoglycemia, um, as well as weight gain. So a couple negatives there

are going for them. But, um, some of the newer class agents, um, have better cardiovascular outcomes, less hypoglycemia risk, less weight gain.

And so, sulfonyureas, glibiride have definitely kind of fallen down the list.

...